🏛️ Verified NIH Record • Updated 2026-08-07

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations (NCT07432958)

Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Appello Pharmaceuticals, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 12 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given. The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and an 8-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

Who can join: Review the eligibility criteria below.

Location: University of Arkansas for Medical Sciences (Site #208) — Little Rock, Arkansas

Age range: 30 Years to 80 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (30 Sites)

Showing the first 25 of 30 sites.

  • University of Arkansas for Medical Sciences (Site #208) — Little Rock, Arkansas
  • Profound Research LLC (Site #222) — Carlsbad, California
  • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217) — Los Alamitos, California
  • Keck Medicine of USC - USC Healthcare Center 2 (Site #221) — Los Angeles, California
  • Parkinson's Research Centers of America (Site #218) — Palo Alto, California
  • Rocky Mountain Clinical Research - CenExel - PPDS (Site #215) — Englewood, Colorado
  • Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227) — Boca Raton, Florida
  • UM-UHealth at Boca Raton (Site #226) — Boca Raton, Florida
  • Velocity Clinical Research - Hallandale Beach (Site #228) — Hallandale, Florida
  • University of Miami (Site #220) — Miami, Florida
  • Neurology One (Site #205) — Orlando, Florida
  • USF Parkinson's Disease and Movement Disorders Center (Site #206) — Tampa, Florida
  • Augusta University Medical Center (Site #212) — Augusta, Georgia
  • Josephson Wallack Munshower Neurology PC (Site #231) — Indianapolis, Indiana
  • The University of Kansas (KU) (Site #216) — Kansas City, Kansas
  • Kentucky Neuroscience Institute (Site #213) — Lexington, Kentucky
  • Beth Israel Deaconess Medical Center (Site #211) — Boston, Massachusetts
  • University of Michigan Health System (UMHS) (Site #202) — Ann Arbor, Michigan
  • Quest Research Institute - Alcanza - PPDS (Site #201) — Farmington Hills, Michigan
  • University of New Mexico Health Sciences Center (Site #225) — Albuquerque, New Mexico
  • Joan and Sanford I. Weill Department of Medicine (Site #224) — New York, New York
  • Mount Sinai School of Medicine (Site #209) — New York, New York
  • Asheville Neurology Specialists, P.A. (Site #229) — Asheville, North Carolina
  • Duke Neurological Disorders Clinic (Site #210) — Durham, North Carolina
  • Cleveland Clinic (Site #223) — Cleveland, Ohio

📞 Contact the Study Coordinator

Phone: (615) 427-1935

Email: annie@appellopharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Parkinson Disease

Explore by condition: All Parkinson Disease clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗